These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 4422210)

  • 21. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. QUAD routes out inferior drugs.
    Can Hosp; 1973 May; 50(5):58-9. PubMed ID: 4779804
    [No Abstract]   [Full Text] [Related]  

  • 23. Benefit and risk information in prescription drug advertising: review of empirical studies and marketing implications.
    Kopp SW; Bang HK
    Health Mark Q; 2000; 17(3):39-56. PubMed ID: 11010219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. U.S. v. Barr Laboratories: a technical perspective.
    Madsen RE
    PDA J Pharm Sci Technol; 1994; 48(4):176-9. PubMed ID: 7804814
    [No Abstract]   [Full Text] [Related]  

  • 25. The Food and Drug Administration's over-the-counter drug review: why review OTC drugs?
    Moxley JH; Yingling GL; Edwards CC
    Fed Proc; 1973 Apr; 32(4):1435-7. PubMed ID: 4701750
    [No Abstract]   [Full Text] [Related]  

  • 26. Expired drugs are not dead drugs.
    Torigian PC
    Am J Hosp Pharm; 1993 Mar; 50(3):448. PubMed ID: 8442459
    [No Abstract]   [Full Text] [Related]  

  • 27. [Harmful effects of drugs. Liability of the manufacturers against insurance claims for damages].
    Dahl B
    Ugeskr Laeger; 1984 Sep; 146(36):2726-8. PubMed ID: 6515894
    [No Abstract]   [Full Text] [Related]  

  • 28. Direct-to-consumer advertising--education or emotion promotion?
    Wolfe SM
    N Engl J Med; 2002 Feb; 346(7):524-6. PubMed ID: 11844857
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug safety and efficacy impaired by quality failure.
    Ekiert RJ
    Pharmazie; 2011 Jun; 66(6):467-9. PubMed ID: 21699091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Riskier than we think? The relationship between risk statement completeness and perceptions of direct to consumer advertised prescription drugs.
    Davis JJ
    J Health Commun; 2000; 5(4):349-69. PubMed ID: 11191018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmaceutical drugs-the good and the not so good: together, we can make it better.
    Campbell AW
    Altern Ther Health Med; 2014; 20(1):9-11. PubMed ID: 24445351
    [No Abstract]   [Full Text] [Related]  

  • 32. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public?
    Levy E
    Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481
    [No Abstract]   [Full Text] [Related]  

  • 33. The impact of the changing health care environment on drug innovation and marketing.
    Flanagan AD
    Ann N Y Acad Sci; 1981; 368():171-4. PubMed ID: 6942775
    [No Abstract]   [Full Text] [Related]  

  • 34. The continuing search for proper perspective: whose reasonableness should be at issue in a prescription product design defect analysis?
    Cupp RL
    Spec Law Dig Health Care Law; 2000 Dec; (260):9-33. PubMed ID: 11149134
    [No Abstract]   [Full Text] [Related]  

  • 35. Prescription drug advertising--should states regulate what is false and misleading?
    Shaeffer J
    Food Drug Law J; 2003; 58(4):629-48. PubMed ID: 15027454
    [No Abstract]   [Full Text] [Related]  

  • 36. [New order in drug legislation].
    Feiden K
    Dtsch Med Wochenschr; 1975 Apr; 100(17):972-6. PubMed ID: 1091438
    [No Abstract]   [Full Text] [Related]  

  • 37. Present attitudes of governmental drug regulatory agencies.
    Noel PR
    Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 39. Generally Regarded As Safe.
    Novack GD
    Ocul Surf; 2017 Jan; 15(1):152-155. PubMed ID: 27871773
    [No Abstract]   [Full Text] [Related]  

  • 40. [Guidelines for introducing new drugs for medical use in Poland and control of their quality].
    Danysz A
    Pol Tyg Lek; 1984 Dec 17-31; 39(51-52):1673-4. PubMed ID: 6522321
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.